Stockholm, March 19, 2009

Last patient recruited in a Phase II study of Kappaproct®

InDex Pharmaceuticals today announced that the last patient has now been recruited to its clinical Phase II study of Kappaproct, for treating steroid resistant/dependent patients with ulcerative colitis of mild to moderate degree.

The study is placebo-controlled, randomized and double-blind and evaluates more than 30 patients at centres in Sweden and Russia.

The primary objective is to evaluate the clinical response of Kappaproct given as a single dose of 30 mg compared to placebo. Patients are monitored for a period of six months after dosing. The study also includes an evaluation of a biomarker test for steroid response. By developing a blood sample test for assessing if a patient is likely to respond to Kappaproct treatment or not - a so called companion diagnostic - InDex follows new guidelines for personalized medicine.

“We are quite excited about this study. A confirmation that the drug can amplify steroid response or re-sensitize non-responding patients to steroids can have significant implications also for other types of chronic inflammation, including asthma and COPD”, says CEO Svante Rasmuson.